Table 2 Response to first-line chemotherapy for patients with CD20-positive HAL treated at King Edward VIII Hospital
| Â | Total n = 102 (%) | CHOP n = 50 (%) | R-CHOP n = 52 (%) | P value (CHOP vs R-CHOP) | |
|---|---|---|---|---|---|
Complete response | 56 (55%) | 23 (46%) | 33 (64%) | 0.147 | |
Total no. of chemotherapy cycles received by 56 patients that achieved CR | 3–5 | 4 (7.2%) | 1 (4.3%) | 3 (9.1%) | 0.240 |
6–8 | 52 (92.8%) | 22 (95.7%) | 30 (90.9%) | ||
Partial response | 7 (7%) | 6 (12%) | 1 (2%) | 0.220 | |
No response/progressive disease* | 14 (14%) | 7 (14%) | 7 (14%) | ||
Lost to follow-up** | 13 (13%) | 7 (14%) | 6 (12%) | ||
Died# | 12 (12%) | 7 (14%) | 5 (10%) | ||
2-year DFS | 47 (46%) | 21 (42%) | 26 (50%) | 0.585 | |
2-year OS | 60 (59%) | 30 (60%) | 30 (58%) | 0.100 | |
Concurrent ART | 86 (84%) | 38 (76%) | 48 (92%) | 0.027 | |
Hospitalization | 29 (28%) | 12 (24%) | 17 (33%) | 0.331 | |
Infections± | 29 (28%) | 13 (26%) | 16 (31%) | 0.594 | |
Infectious complications CD4 > 50 cells/μL (n = 91) | 25 (28%) | 10/42 (23%) | 15/49 (30%) | 0.381 | |
Received red cell transfusion | 27 (26%) | 9 (18%) | 18 (35%) | 0.057 | |
Received granulocyte colony-stimulating factor | 35 (34%) | 17 (34%) | 18 (35%) | 0.915 | |